Abstract: Dabigatran etexilate and rivaroxaban, as two representative new oral anticoagulants, have been widely used in clinical anticoagulation due to their fixed dosage and superior safety. However,for special populations, precise medication based on pharmacogenomics is still necessary.Most of the existing research data confirm that multiple drug gene polymorphisms are closely related to the patient's blood drug concentration and/or stroke events, but some studies have reached conflicting conclusions. Therefore, this article intends to take the genetic polymorphism as the starting point to review the research progress related to the pharmacogenomics of Dabigatran Etexilate and Rivaroxaban, in order to expand the individual differences in people’s response to Dabigatran Etexilate and Rivaroxaban.

Key words: pharmacogenomics, Dabigatran Etexilate, Rivaroxaban, gene polymorphism